The economics of topical immunomodulators for the treatment of atopic dermatitis

PharmacoEconomics

Volumn 23, Issue 6, 2005, Pages 543-566

  Abramovits, William ^a   Boguniewicz, Mark ^b   Paller, Amy S ^c   Whitaker Worth, Diane L ^d   Prendergast, Mary M ^e   Tokar, Michael ^f   Tong, Kuo B ^a,f  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e ASTELLAS PHARMA INC   (Japan)

^f Quorum Consulting Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; TACROLIMUS;

ACNE; ADOLESCENCE; ADRENAL SUPPRESSION; ANTIBIOTIC THERAPY; ATOPIC DERMATITIS; AUSTRALIA; BACTERIAL INFECTION; BODY SURFACE; CARCINOGENICITY; CATARACT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CREAM; DENMARK; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; FACE; FOLLICULITIS; GERMANY; GINGIVA HYPERPLASIA; GLAUCOMA; GROWTH RETARDATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; HYPOPIGMENTATION; ITALY; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; MYCOSIS; NEPHROTOXICITY; NETHERLANDS; NEW ZEALAND; NONHUMAN; OINTMENT; PERIORAL DERMATITIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RATING SCALE; REVIEW; ROSACEA; SCORING SYSTEM; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN INFECTION; SKIN MANIFESTATION; STRIA; SWEDEN; SYSTEMIC DISEASE; TELANGIECTASIA; TOPICAL TREATMENT; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; UNITED KINGDOM; UNITED STATES; VIRUS INFECTION;

ADMINISTRATION, TOPICAL; COST OF ILLNESS; DERMATITIS, ATOPIC; HUMANS; IMMUNOLOGIC FACTORS;

EID: 22244487998     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523060-00003     Document Type: Review

References (83)

1. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999 Jan; 103 (1 Pt 1): 125-38
2. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996 May; 34 (5 Pt 1): 760-4
3. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000 Oct; 43 (4): 649-55
4. Sugiura H, Umemoto N, Deguchi H, et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998 Jul; 78 (4): 293-4
5. Ellis C, Drake L, Prendergast M, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002 Mar; 46: 361-70
6. Boguniewicz M, Leung DYM. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001; 20 (4): 217-25
7. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S1-12
8. Lapidus CS, Honig PJ. Atopic dermatitis. Pediatr Rev 1994 Aug; 15 (8): 327-32
9. Boguniewicz M, Leung DY. Atopic dermatitis. In: Middleton E, Ellis EF, Yunginger JW, et al., editors. Allergy: principles and practice, 5th ed. St Louis (MO): Mosby, 1998: 1123-31
10. Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999 Sep 15; 60 (4): 1191-8, 1209-10
11. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S13-6
12. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003 May; 148 Suppl. 63: S3-10
13. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4 (37): 1-191
14. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 539-46
15. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 May; 142 (5): 931-6
16. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000 Jan; 142 (1): 52-8
17. Klasco RK, Gelman CR, editors. USP DI® drug information for the healthcare professional. Greenwood Village (CO): Micromedex, 2003
18. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71 (5): 452-4
19. Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S17-27
20. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002 Feb; 46 (2): 228-41
21. Red book, Montvale (NJ): Medical Economics, 2004 Jan
22. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I. Efficacy. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S28- 38
23. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S47-57
24. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998 Oct; 102 (4 Pt 1): 637-44
25. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337 (12): 816-21
26. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 557-5
27. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S58-64
28. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136 (8): 999-1006
29. Hanifin JM, Leung DY, Paller A, et al. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patients [abstract]. American Academy of Allergy, Asthma and Immunology 60th Anniversary Meeting; 2003 Mar 7-12; Denver. 244
30. Koo JY, Fleischer A, Pariser D, et al. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7,000 patients) open-label study [abstract]. American Academy of Dermatology Conference; 2003 Mar 21-26; San Francisco. P22
31. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 Feb; 142 (2): 155-62
32. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110 (1 Pt 1): e2
33. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002 Aug; 110 (2): 277-84
34. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 Apr; 46 (4): 495-504
35. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 788-94
36. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-7
37. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 Mar; 144 (3): 507-13
38. Soter NA, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S39-46
39. Fleischer Jr AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002 Oct; 47 (4): 562-70
40. Protopic package insert. Deerfield (IL): Fujisawa Healthcare, Inc., 2000
41. Elidel package insert. East Hanover (NJ): Novartis Pharmaceuticals, 2003
42. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998 Jan; 38 (1): 69-76
43. Schnopp C, Remling R, Möhrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002 Jan; 46 (1): 73-7
44. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 Oct; 51 (4): 515-25
45. Paller AS, Lebwohl M, Fleischer Jr AB, et al. Tacrolimus ointment is more effective that pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005 May; 52 (5): 810-22
46. Fleischer AB. Controlling atopic dermatitis with Protopic: new insights. Oral presentation at the 12th Congress of the European Academy of Dermatology and Venereology; 2003 Oct 15-18; Barcelona, Spain
47. Lapidus CS. Role of social factors in atopic dermatitis: the US perspective. J Am Acad Dermatol 2001 Jul; 45 (1 Suppl.): S41-3
48. Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-31
49. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol 1993; 28 (5 Pt 1): 699-703
50. Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993 Mar; 28 (3): 422-5
51. Ward MM, Javitz HS, Smith WM, et al. Direct medical cost of chronic obstructive pulmonary disease in the USA. Respir Med 2000 Nov; 94 (11): 1123-9
52. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000 Mar; 41 (3): 342-51
53. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 144 (3): 514-22
54. Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135: 20-3
55. Gieler U, Hohmann M, Niemeier V, et al. Cost evaluation in atopic eczema. J Dermatol Treat 1999; 10: S15-20
56. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76 (2): 159-62
57. Fivenson D, Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and QOL on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8 (5): 333-41
58. Finlay AY. QOL in atopic dermatitis. J Am Acad Dermatol 2001 Jul; 45 (1 Suppl.): S64-6
59. Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child 1993 Dec; 69 (6): 670-6
60. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001 Sep; 84 (9): 294-5
61. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, et al. Sleep disturbance in children with atopic dermatitis. Arch Pediatr Adolesc Med 1994 Aug; 149 (8): 856-60
62. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related QOL of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S65-72
63. Finlay AY. Measures of the effect of adult severe atopic eczema on QOL. J Eur Acad Dermatol Venereol 1996 Sep; 7 (2): 149- 54
64. Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999 Feb; 140 (2): 268-72
65. Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol 1995 Jan; 20 (1): 38-41
66. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on QOL: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003; 21 (3): 159-79
67. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19 (3): 210-6
68. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995 Jun; 132 (6): 942-9
69. Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' QOL in the treatment of pediatric atopic dermatitis. Pediatrics 2002 Dec; 110 (6): 1133-6
70. Whalley D, McKenna SP, Dewar AL, et al. International development of a measure to assess QOL in childhood atopic dermatitis -the PIQoL-AD. Qual Life Res 2000; 9: 302
71. Whalley D, McKenna S, Huels J, et al. Pimecrolimus (SDZ ASM 981) in the treatment of paediatric atopic eczema: benefit to QOL and health related QOL [abstract PO284]. 20th World Congress of Dermatology Conference; 2002 Jul 1-5; Paris
72. Whalley D, McKenna S, Huels J, et al. Pimecrolimus (SDZ ASM 981) in the treatment of atopic eczema: benefit to QOL among infants [abstract PO283]. 20th World Congress of Dermatology Conference; 2002 Jul 1-5; Paris
73. Ellis CN, Reiter KL, Wheeler JR, et al. Economic analysis in dermatology. J Am Acad Dermatol 2002 Feb; 46 (2): 271-8
74. Lundberg L, Johannesson M, Silverdahl M, et al. QOL, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-79: e28
75. Friedman JY, Reed SD, Weinfurt KP, et al. Parents' perception of the QOL impact of childhood atopic dermatitis disease states [abstract]. American Academy of Dermatology Conference; 2003 Mar 21-26; San Francisco. 19
76. Ellis C, Drake L, Prendergast M, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2003 Apr; 48 (4): 553-63
77. Ellis CN, Kahler K, Grueger J. Long-term management of atopic dermatitis with pimecrolimus cream 1%: an economic analysis [abstract]. American Academy of Dermatology Conference; 2003 Mar 21-26; San Francisco. P205
78. Verboom P, Hakkaart-van Roijen L, Rutten F, et al. The cost effectiveness of pimecrolimus (SDZ ASM 981) topical cream 1% and corticosteroids in the treatment of atopic dermatitis [abstract]. American Academy of Dermatology Conference; 2003 Mar 21-26; San Francisco. 279
79. Abramovits W, Boguniewicz M, Prendergast MM, et al. Com parisons of efficacy and cost effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003; 6: 1-14
80. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 Feb; 10 (1): 11-8
81. Arikian SR, Einarson TR, Doyle JJ. Economic evaluation of treatments for eczema and atopic dermatitis. In: Rajagopalan R, Sherertz EF, Anderson RT, editors. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker, 1998: 317-40
82. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother 2002 Mar; 3 (3): 249-55
83. Williams H. Another vehicle-controlled study of 1% pimecrolimus in atopic dermatitis: how does it help clinicians and patients, and is it ethically sound? Arch Dermatol 2002 Dec; 138 (12): 1602-3